Why CUE-221 Might Not Beat Omalizumab In CSU And Could Still Separate In Food Allergy
A Phase 2 comparing the "dual-mechanism" anti-IgE with omalizumab in CSU is expected to read out this quarter. Ligelizumab showed how hard beating omalizumab is. Why the IgE levels may indicate whether CUE-221 could still separate in food allergy.